greater in the PLLA-SCA group, versus the control, at month 7 (66.2% versus 38.6%; P=0.0043) and at month 9 (70.6% versus 31.1%; P<0.0001).
GCWS dynamic responder rate (live blinded evaluator assessment) was significantly higher in the PLLA-SCA group versus the control at months 7 (67.5% versus 27.3%; P<0.0001), 9 (64.7% versus 22.2%; P<0.0001), and 12 (70.5% versus 28.3%; P<0.0001; Figure 3).
Treating investigator-reported GAIS responder rate was 68.1% at month 1 and >92% from month 7 onwards in the PLLA-SCA group and <7% throughout the study period in the control group (Figure 4). After the PLLA-SCA injection, treating investigators agreed/strongly agreed that skin radiance was improved (>95%), skin appeared tighter (>88%) and the jawline contour was improved (>85%; Table 3).
From month 7 through month 12, subject satisfaction questionnaires revealed that most PLLA-SCA recipients reported treatment results to be excellent, very good, good, or satisfactory regarding improvement in skin radiance (greater than or equal to 90%), sagging (greater than or equal to 84%) and firmness (greater than or equal to 91%). Most PLLA-SCA subjects saw improvements regarding looking younger (greater than or equal to 90%) and
